Prostate Stereotactic Body Radiotherapy - First UK Experience

Clinical Oncology

Volumn 26, Issue 12, 2014, Pages 757-761

  Tree, A C ^a   Ostler, P ^b   Hoskin, P ^b   Dankulchai, P ^b   Nariyangadu, P ^b   Hughes, R J ^b   Wells, E ^a   Taylor, H ^a   Khoo, V S ^a,c   van As, N J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Prostate; SBRT; Stereotactic body radiotherapy; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE TOXICITY; ARTICLE; CANCER RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HISTOGRAM; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; UNITED KINGDOM; URINARY FREQUENCY; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; CANCER STAGING; COHORT ANALYSIS; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIOSURGERY;

COHORT STUDIES; GREAT BRITAIN; HUMANS; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 84911482699     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.08.007     Document Type: Article

References (32)

1. Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol 2011, 6:3.
2. Friedland J.L., Freeman D.E., Masterson-McGary M.E., et al. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009, 8(5):387-392.
3. Katz A.J., Santoro M., Diblasio F., et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013, 8(1):118.
4. Katz A. Five-year biochemical control rates for stereotactic body radiotherapy for organ confined prostate cancer: a multi-institutional pooled analysis, Oral presentation at ASTRO annual meeting. Int J Radiat Oncol Biol 2012, 84(3Suppl):s147-s148.
5. Meier R., Kaplan I., Beckman A., et al. stereotactic body radiotherapy for intermediate-risk organ-confined prostate cancer: interim toxicity and quality of life outcomes from a multi-institutional study. Int J Radiat Oncol Biol Phys 2012, 84(3):S148.
6. Alongi F., Cozzi L., Arcangeli S., et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 2013, 8(1):171.
7. Loblaw A., Cheung P., D'Alimonte L., et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013, 107(2):153-158.
8. Chao K.K., Goldstein N.S., Yan D., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65(4):999-1007.
9. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999, 85(12):2630-2637.
10. Chang S.D., Main W., Martin D.P., et al. An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system. Neurosurgery 2003, 52(1):140-146. discussion 146-147.
11. Kilby W., Dooley J.R., Kuduvalli G., et al. The CyberKnife robotic radiosurgery system in 2010. Technol Cancer Res Treat 2010, 9(5):433-452.
12. Xie Y., Djajaputra D., King C.R., et al. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72(1):236-246.
13. Katz A.J., Santoro M., Ashley R., et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010, 10:1.
14. Dasu A., Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012, 51(8):963-974.
15. Miralbell R., Roberts S.A., Zubizarreta E., et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 2012, 82(1):e17-24.
16. Tree A.C., Khoo V.S., van As N.J., et al. Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?. Clin Oncol (RColl Radiol) 2014, 26(4):216-229.
17. Tree A.C., Alexander E.J., Van As N.J., et al. Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?. Clin Oncol (R Coll Radiol) 2013, 25(8):483-498.
18. Khoo V.S., Dearnaley D.P. Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer - the CHHiP trial. Clin Oncol (R Coll Radiol) 2008, 20(1):12-14.
19. Dearnaley D., Syndikus I., Sumo G., et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13(1):43-54.
20. Zelefsky M.J., Kollmeier M., Cox B., et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 84(1):125-129.
21. Park S.S., Yan D., McGrath S., et al. Adaptive image-guided radiotherapy (IGRT) eliminates the risk of biochemical failure caused by the bias of rectal distension in prostate cancer treatment planning: clinical evidence. Int J Radiat Oncol Biol Phys 2012, 83(3):947-952.
22. Kok D., Gill S., Bressel M., et al. Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol 2013, 107(2):140-146.
23. King C.R., Freeman D., Kaplan I., et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013, 109(2):217-221.
24. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Aprostate specific antigen (PSA) bounce greater than 1.4 ng/mL is clinically significant after external beam radiotherapy for prostate cancer. Am J Clin Oncol 2006, 29(5):458-462.
25. Mehta N.H., Kamrava M., Wang P.C., et al. Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 86(4):729-733.
26. Bolzicco G., Favretto M.S., Satariano N., et al. Asingle-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013, 13(1):49.
27. Park C., Papiez L., Zhang S., et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(3):847-852.
28. Kolesnick R., Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22(37):5897-5906.
29. Park H.J., Griffin R.J., Hui S., et al. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 2012, 177(3):311-327.
30. The PACE trial registered at . 1 October 2013. [accessed 20.06.14]. http://www.clinicaltrials.gov/ct2/show/NCT01584258.
31. Tree A., Aluwini A., Bryant H., et al. Successful patient acceptance of randomization within the PACE study (Prostate Advances in Comparative Evidence). Int J Radiat Oncol Biol Phys 2013, 87(2):S365.
32. ASTRO prostate SBRT guidelines: ASTRO model policies Stereotactic Body RadioTherapy (SBRT). Published 2013. [accessed 20.06.14]. Available at: . http://www.astro.org/uploadedFiles/Main_Site/Practice:Management/Reimbursement/2013HPcoding%20guidelines_SBRT_Final.pdf.